BIOMAT Database Logo BIOMAT Database Logo

Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. 1970

A M Watanabe, and T N Chase, and P V Cardon

UI MeSH Term Description Entries
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012018 Reflex An involuntary movement or exercise of function in a part, excited in response to a stimulus applied to the periphery and transmitted to the brain or spinal cord.
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003250 Constriction The act of constricting. Clamping,Clampings,Constrictions
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005542 Forearm Part of the upper extremity in humans and primates extending from the ELBOW to the WRIST. Antebrachium,Antebrachiums,Forearms

Related Publications

A M Watanabe, and T N Chase, and P V Cardon
[Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
March 1973, Archiv fur Psychiatrie und Nervenkrankheiten,
A M Watanabe, and T N Chase, and P V Cardon
Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
November 1983, Pediatric research,
A M Watanabe, and T N Chase, and P V Cardon
Effects of L-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs.
May 1971, Experientia,
A M Watanabe, and T N Chase, and P V Cardon
Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs.
July 1977, The Journal of pharmacology and experimental therapeutics,
A M Watanabe, and T N Chase, and P V Cardon
Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
February 1973, Journal of neurology, neurosurgery, and psychiatry,
A M Watanabe, and T N Chase, and P V Cardon
[Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
December 1972, Minerva medica,
A M Watanabe, and T N Chase, and P V Cardon
[Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
February 1975, La Nouvelle presse medicale,
A M Watanabe, and T N Chase, and P V Cardon
[L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
March 1974, Nihon rinsho. Japanese journal of clinical medicine,
A M Watanabe, and T N Chase, and P V Cardon
[Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
July 1970, Arzneimittel-Forschung,
A M Watanabe, and T N Chase, and P V Cardon
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.
September 1971, British medical journal,
Copied contents to your clipboard!